BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program. The notice of allowance was issued on February 24, 2023.
https://finance.yahoo.com/news/biorestorative-therapies-receives-notice-allowance-123000515.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.